Cassava Sciences, Inc. (SAVA)
Stock Price:
$7.76 USD
0.00 (0.00%)
Updated November 27, 1:00 PM EST - Market closed
Pre-market: $7.50 -0.26 (-3.35%) Nov 30, 6:17 AM
Key Info
| Market Cap |
198.49M |
| Revenue (ttm) |
n/a |
| Net Income (ttm) |
-5.23M |
| Shares Out |
25.58M |
| EPS (ttm) |
-0.23 |
| PE Ratio |
n/a |
| Forward PE |
34.01 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
November 27 |
| Last Price |
$7.76 |
| Previous Close |
$7.76 |
| Change ($) |
0.00 |
| Change (%) |
0.00% |
| Day's Open |
7.93 |
| Day's Range |
7.60 - 7.94 |
| Day's Volume |
1,645,209 |
| 52-Week Range |
1.65 - 12.25 |
More Stats
| Market Cap |
198.49M |
| Enterprise Value |
174.73M |
| Earnings Date (est) |
Jan 1, 1970 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
25.58M |
| Float |
n/a |
| EPS (basic) |
-0.25 |
| EPS (diluted) |
-0.23 |
| FCF / Share |
-0.18 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
5.99M |
| Short Ratio |
1.41 |
| Short % of Float |
n/a |
| Beta |
1.89 |
| PE Ratio |
n/a |
| Forward PE |
34.01 |
| P/FCF Ratio |
n/a |
| PS Ratio |
n/a |
| PB Ratio |
10.57 |
| Revenue |
n/a |
| Operating Income |
-5.40M |
| Net Income |
-5.23M |
| Free Cash Flow |
-4.44M |
| Net Cash |
23.76M |
| Net Cash / Share |
0.93 |
| Gross Margin |
n/a |
| Operating Margin |
n/a |
| Profit Margin |
n/a |
| FCF Margin |
n/a |
| ROA |
-16.40% |
| ROE |
-25.26% |
| ROIC |
975.70% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Forecasts
Analyst Ratings (3)
| Buy |
3 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$19.33*
(149.10% upside)
Low
14.0
Current: $7.76
High
24.0
Target: 19.33
*Average 12-month price target from 3 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|
| Revenue | - | - | - | - | - | - | 41.12 | 10.89 | 11.48 | 16.81 |
| Revenue Growth | - | - | - | - | - | - | 277.58% | -5.17% | -31.68% | - |
| Gross Profit | - | - | - | - | - | - | 41.12 | 10.89 | 11.48 | 16.81 |
| Operating Income | -4.96 | -6.66 | -11.95 | -14.96 | -14.20 | -12.43 | 31.37 | -3.90 | -3.51 | -13.70 |
| Net Income | -4.63 | -6.56 | -11.91 | -14.85 | -14.15 | -12.39 | 31.54 | -3.45 | -2.61 | -12.02 |
| Shares Outstanding | 17.41 | 10.68 | 6.54 | 6.52 | 6.48 | 6.47 | 6.43 | 6.39 | 6.31 | 6.09 |
| Earnings Per Share | -0.27 | -0.61 | -1.82 | -2.28 | -2.17 | -1.89 | 4.90 | -0.56 | -0.42 | -1.96 |
| Dividend Per Share | - | - | - | - | - | - | - | 5.25 | - | 14.00 |
| Operating Cash Flow | -2.51 | -4.77 | -8.24 | -12.23 | -9.05 | -9.55 | -6.95 | -7.17 | -0.26 | -0.14 |
| Capital Expenditures | -0.02 | - | - | -0.08 | -0.20 | -0.08 | - | - | - | - |
| Free Cash Flow | -2.53 | -4.77 | -8.24 | -12.31 | -9.25 | -9.63 | -6.95 | -7.17 | -0.26 | -0.14 |
| Cash & Equivalents | 23.08 | 19.81 | 10.48 | 18.71 | 31.30 | 40.59 | 49.84 | 56.25 | 98.13 | 91.23 |
| Total Debt | 0.09 | - | - | - | - | - | - | - | - | - |
| Net Cash / Debt | 22.99 | 19.81 | 10.48 | 18.71 | 31.30 | 40.59 | 49.84 | 56.25 | 98.13 | 91.23 |
| Assets | 23.49 | 20.14 | 10.83 | 19.30 | 31.92 | 40.91 | 50.10 | 56.86 | 98.96 | 99.20 |
| Liabilities | 1.39 | 0.51 | 1.13 | 0.67 | 2.55 | 0.85 | 1.80 | 43.72 | 54.57 | 66.26 |
| Book Value | 22.10 | 19.63 | 9.70 | 18.64 | 29.37 | 40.06 | 48.30 | 13.14 | 44.39 | 32.93 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Cassava Sciences, Inc. |
| Country |
United States |
| Employees |
9 |
| CEO |
Remi Barbier |
Stock Information
| Ticker Symbol |
SAVA |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: SAVA |
Description
Cassava Sciences, a clinical stage biotechnology company, develops drugs for nervous system disorders. Its lead therapeutic product candidate is PTI-125, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was founded in 1998 and is based in Austin, Texas.